Xu T, Qi X, Zhao FY, Qian NS. The triglyceride-glucose index shows promise as a novel prognostic marker for advanced hepatocellular carcinoma. World J Gastroenterol 2026; 32(2): 115178 [DOI: 10.3748/wjg.v32.i2.115178]
Corresponding Author of This Article
Fei-Yu Zhao, PhD, Doctor, Department of Radiation Oncology, The Fifth Medical Center of Chinese People’s Liberation Army General Hospital, No. 8 East Main Street, Fengtai District, Beijing 100071, China. 1029279130@qq.com
Research Domain of This Article
Oncology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jan 14, 2026 (publication date) through Jan 12, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Xu T, Qi X, Zhao FY, Qian NS. The triglyceride-glucose index shows promise as a novel prognostic marker for advanced hepatocellular carcinoma. World J Gastroenterol 2026; 32(2): 115178 [DOI: 10.3748/wjg.v32.i2.115178]
World J Gastroenterol. Jan 14, 2026; 32(2): 115178 Published online Jan 14, 2026. doi: 10.3748/wjg.v32.i2.115178
The triglyceride-glucose index shows promise as a novel prognostic marker for advanced hepatocellular carcinoma
Tao Xu, Xu Qi, Fei-Yu Zhao, Nian-Song Qian
Tao Xu, Nian-Song Qian, Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, Beijing 100091, China
Xu Qi, Department of Radiology, Peking Union Medical College Hospital, Beijing 100730, China
Fei-Yu Zhao, Department of Radiation Oncology, The Fifth Medical Center of Chinese People’s Liberation Army General Hospital, Beijing 100071, China
Co-first authors: Tao Xu and Xu Qi.
Co-corresponding authors: Fei-Yu Zhao and Nian-Song Qian.
Author contributions: Xu T and Qi X wrote and revised the manuscript; Zhao FY and Qian NS gave notes and suggestions.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fei-Yu Zhao, PhD, Doctor, Department of Radiation Oncology, The Fifth Medical Center of Chinese People’s Liberation Army General Hospital, No. 8 East Main Street, Fengtai District, Beijing 100071, China. 1029279130@qq.com
Received: October 10, 2025 Revised: November 16, 2025 Accepted: December 23, 2025 Published online: January 14, 2026 Processing time: 94 Days and 15.9 Hours
Abstract
This commentary critically appraises the study by Li et al which pioneered the exploration of the triglyceride-glucose (TyG) index as a prognostic marker in hepatitis B virus-related advanced hepatocellular carcinoma patients undergoing combined camrelizumab and lenvatinib therapy. While we acknowledge the study’s clinical relevance in proposing an easily accessible metabolic biomarker, we delve into the mechanistic plausibility linking insulin resistance to immunotherapy response and angiogenic inhibition. We further critically examine the methodological limitations, including the retrospective design, the population-specific TyG cut-off value, and unaddressed metabolic confounders. We highlight the imperative for future research to validate its utility across diverse etiologies and treatment settings, and to unravel the underlying immunometabolic pathways.
Core Tip: This commentary highlights triglyceride-glucose (TyG) index as a prognostic marker for hepatitis B virus-related advanced hepatocellular carcinoma on camrelizumab-lenvatinib. Low TyG (< 1.58) boosts survival, it’s an independent predictor, with limitations needing multicenter studies.
